1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Philips NV
  6. News
  7. Summary
    PHIA   NL0000009538


Real-time Euronext Amsterdam  -  05/26 11:35:25 am EDT
23.67 EUR   +2.18%
05/25JPMorgan Downgrades Koninklijke Philips to Underweight From Neutral
05/25Philips Foundation publishes its 2021 Annual Report
05/25Philips Foundation publishes its 2021 Annual Report
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Philips introduces first at-home, 12-lead ECG integrated solution for decentralized clinical trials

01/26/2022 | 04:00am EDT

January 26, 2022

Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during clinical trials

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of the industry’s first full-service, at-home, 12-lead electrocardiogram (ECG) solution for use in decentralized clinical trials. The clinical-grade solution is the most advanced patient-centric ECG offering within the company’s cardiac monitoring portfolio, pairing data readings comparable to clinical, site-based ECGs with Philips leading cloud-based data collection and analysis services. This latest addition to Philips’ digitally enabled suite of monitoring solutions helps to drive innovation across the care continuum and support the decentralized clinical trial space.

Patient attrition is one of the biggest issues faced by clinical trial sponsors seeking regulatory approval for new therapies. Attrition over the course of a study can reduce the quality of its findings and can lead to longer, more expensive trials that require higher than optimal recruiting rates to compensate. Voluntary patient withdrawal is often tied to disease progression or the prolonged inconvenience of adhering to protocol regimens and repetitive site visits [1]. By offering the consistent and reliable standards of a 12-lead ECG in the comfort and convenience of a patient’s home, Philips at-home ECG solution aims to improve trial recruitment, compliance and patient retention by reducing the need for and burden of site visits.

“Our customers are seeking solutions that will help them to address key challenges that can stand in the way of extracting meaningful insights from their clinical trials,” said Andy Broadway, General Manager of Ambulatory Monitoring and Diagnostics at Philips. “Our growing portfolio of remote monitoring solutions help to curb patient attrition by reducing the amount of site visits required during the trial period, helping to improve both the quality of the outcome and the patient experience overall.”

Leveraging PCA 500 ECG patch data recording technology, the at-home solution allows clinical trial participants to record data with quality comparable to site-based ECGs at home. The solution’s innovative body-worn patch ensures compliant 12-lead ECG placement and near real-time, highly secure data transmission without the need for recurring site visits, onsite technician, or home nurses.

Philips offers a complete range of clinically validated ambulatory cardiac diagnostics and monitoring services and associated expertise to its cardiac care portfolio, including its BioTel Research capabilities that have already supported more than 2,000 clinical trials in 72 countries. These comprehensive offerings provide industry-leading technology and data management that streamlines the clinical trials process and ensures optimal performance. The at-home, 12-lead ECG solution is now available in select markets across North America, Europe and Asia.

[1] Hui D, Glitza I, Chisholm G, Yennu S, Bruera E. Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer. 2013;119(5):1098-1105. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568443/

For further information, please contact:

Meredith Amoroso
Philips Global Press Office
Tel: +1 724-584-8991
E-mail: meredith.amoroso@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


  • Philips introduces first at-home, 12 lead ECG integrated solution for decentralized clinical trials
  • Philips new at-home, 12 lead ECG solution helps to reduce need for site visits during clinical trials

© OMX, source GlobeNewswire - EU Press Releases

All news about PHILIPS NV
05/25JPMorgan Downgrades Koninklijke Philips to Underweight From Neutral
05/25Philips Foundation publishes its 2021 Annual Report
05/25Philips Foundation publishes its 2021 Annual Report
05/25PHILIPS NV : JP Morgan lowers its rating to Sell
05/24PHILIPS : Respironics provides update on filed MDRs in connection with the voluntary recal..
05/20PHILIPS NV : JP Morgan reiterates its Neutral rating
05/17Royal Philips - New release of Philips EchoNavigator helps interventional teams treat s..
05/16Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022
05/16Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022
05/16New release of Philips EchoNavigator helps interventional teams treat structural heart ..
More news
Analyst Recommendations on PHILIPS NV
More recommendations
Sales 2022 18 272 M 19 511 M 19 511 M
Net income 2022 806 M 861 M 861 M
Net Debt 2022 4 281 M 4 572 M 4 572 M
P/E ratio 2022 24,0x
Yield 2022 3,83%
Capitalization 20 137 M 21 503 M 21 503 M
EV / Sales 2022 1,34x
EV / Sales 2023 1,24x
Nbr of Employees 78 189
Free-Float 97,5%
Duration : Period :
Philips NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHILIPS NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 23,17 €
Average target price 31,67 €
Spread / Average Target 36,7%
EPS Revisions
Managers and Directors
Frans van Houten Chief Executive Officer
Abhijit Bhattacharya Chief Financial Officer & Executive Vice President
Feike Sijbesma Chairman-Supervisory Board
Jan Kimpen Chief Medical Officer
Sophie Bechu Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
PHILIPS NV-29.30%21 503